DK0607776T3 - Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa - Google Patents

Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa

Info

Publication number
DK0607776T3
DK0607776T3 DK94100016T DK94100016T DK0607776T3 DK 0607776 T3 DK0607776 T3 DK 0607776T3 DK 94100016 T DK94100016 T DK 94100016T DK 94100016 T DK94100016 T DK 94100016T DK 0607776 T3 DK0607776 T3 DK 0607776T3
Authority
DK
Denmark
Prior art keywords
necrosis factor
factor alpha
leflunomide
tumor necrosis
inhibit tumor
Prior art date
Application number
DK94100016T
Other languages
Danish (da)
English (en)
Inventor
Klaus Ulrich Dr Weithmann
Robert Ryder Dr Bartlett
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0607776T3 publication Critical patent/DK0607776T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94100016T 1993-01-08 1994-01-03 Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa DK0607776T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4300280 1993-01-08

Publications (1)

Publication Number Publication Date
DK0607776T3 true DK0607776T3 (da) 1999-08-16

Family

ID=6477855

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94100016T DK0607776T3 (da) 1993-01-08 1994-01-03 Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa

Country Status (8)

Country Link
US (1) US5547970A (es)
EP (1) EP0607776B1 (es)
JP (1) JPH06234637A (es)
AT (1) ATE174219T1 (es)
DE (1) DE59407414D1 (es)
DK (1) DK0607776T3 (es)
ES (1) ES2124801T3 (es)
GR (1) GR3029490T3 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
AU3130597A (en) 1996-05-16 1997-12-05 Duke University Tristetraprolin
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19702988A1 (de) 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
JP4581137B2 (ja) * 1998-03-11 2010-11-17 ジェームス ダブリュ． ウィリアムズ， レフルノミド産物の抗ウイルス用途
US6184246B1 (en) 1999-07-30 2001-02-06 The United States Of America As Represented By The Secretary Of Agriculture Inhibition of cytokine production by polymethoxylated flavones
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
EP1578782A4 (en) * 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
CA2567602A1 (en) * 2004-05-21 2006-01-05 The Uab Research Foundation Compositions and methods relating to pyrimidine synthesis inhibitors
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
DE69132470D1 (de) * 1990-08-06 2000-12-21 Chiron Corp Verfahren zum nachweis von cytokinkonvertasehemmern

Also Published As

Publication number Publication date
ATE174219T1 (de) 1998-12-15
DE59407414D1 (de) 1999-01-21
US5547970A (en) 1996-08-20
GR3029490T3 (en) 1999-05-28
EP0607776A3 (es) 1994-08-31
EP0607776B1 (de) 1998-12-09
JPH06234637A (ja) 1994-08-23
ES2124801T3 (es) 1999-02-16
EP0607776A2 (de) 1994-07-27

Similar Documents

Publication Publication Date Title
DK0607776T3 (da) Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa
DK0607775T3 (da) Anvendelse af leflunomid til inhibering af interleukin 1 beta
DE122006000010I2 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in derBehandlung von kardiovaskularen Krankheiten
BR9805544C1 (pt) Uso de um composto.
ATE63906T1 (de) 3,5-disubstituierte 4,5-dihydroisoxazole als transglutaminasehemmer.
ATE210440T1 (de) Behandlung von tumoren mit verbindungen mit einer rxr-retinoid agonistische wirkung
ATE156482T1 (de) 1,4,5-triphenyl-pyrazolverbindungen zur behandlumg von entzündungen und entzündungsverwandten störungen
BR9609503A (pt) Composto, uso de um composto, processo de tratamento de condições onde a inibição de pde especìfico para cgmp é de benefìcio terapêutico, em corpo de animal humano ou não humano, composição farmacêutica, e processos para preparar a mesma e um composto
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE187965T1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
SE8104625L (sv) Anvending av aromatas-hemmare for profylax och terapi av prostatahyperplasi
DK0607777T3 (da) Anvendelse af leflunomid til inhibering af interleukin 8
FI820115L (fi) Tetrahydronaftalen- och indanfoereningar
ES2068194T3 (es) Alfa-aminoacidos substituidos que tienen actividad farmaceutica.
EA200001124A1 (ru) Способ генной терапии
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DK0607774T3 (da) Anvendelse af leflunomid til inhibering af interleukin 1 alfa
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE342352T1 (de) Entwurf und verwendung von verbesserten zink- chelatbildenden peptiden zur regulation von matrix-metalloproteinasen
DE3684825D1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE60118924D1 (de) Verwendung des riluzols oder dessen salzen zur phophylaxe und behandlung der adrenoleukodystrophie